Lantheus Holdings, Inc. $LNTH Shares Bought by Retirement Systems of Alabama

Retirement Systems of Alabama raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,010 shares of the medical equipment provider’s stock after purchasing an additional 25,967 shares during the period. Retirement Systems of Alabama’s holdings in Lantheus were worth $18,514,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. ABS Investment Management LLC acquired a new stake in shares of Lantheus during the 2nd quarter valued at about $232,974,000. Western Wealth Management LLC acquired a new position in Lantheus in the first quarter worth approximately $25,000. USA Financial Formulas acquired a new position in Lantheus in the third quarter worth approximately $41,000. Allworth Financial LP acquired a new position in Lantheus in the second quarter worth approximately $49,000. Finally, Bessemer Group Inc. raised its position in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH opened at $101.60 on Thursday. The company has a market capitalization of $6.64 billion, a PE ratio of 25.02 and a beta of 0.01. Lantheus Holdings, Inc. has a one year low of $51.47 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 3.06. The company’s fifty day moving average price is $100.30 and its 200 day moving average price is $92.57.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.45. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The firm had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. During the same quarter in the previous year, the business earned $1.27 EPS. The business’s revenue was up 1.5% on a year-over-year basis. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent research reports. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Weiss Ratings downgraded shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 15th. Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. B. Riley Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, William Blair set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $107.44.

About Lantheus

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.